Pathogen-reduced Ebola virus convalescent plasma: first steps towards standardization of manufacturing and quality control including assessment of Ebola-specific neutralizing antibodies

Vox Sanguinis
C GeisenR Schäfer

Abstract

Ebola virus disease is a public health emergency of international concern, and enormous efforts are being made in the development of vaccines and therapies. Ebola virus convalescent plasma is a promising anti-infective treatment of Ebola virus disease. Therefore, we developed and implemented a pathogen-reduced Ebola virus convalescent plasma concept in accordance with national, European and global regulatory framework. Ebola virus convalescent plasma manufacture and distribution was managed by a collection centre, two medical centres and an expert group from the European Blood Alliance. Ebola virus convalescent plasma was collected twice with an interval of 61 days from a donor recovering from Ebola virus disease in Germany. After pathogen reduction, the plasma was analysed for Ebola virus-specific immunoglobulin G (IgG) antibodies and its Ebola virus neutralizing activity. Convalescent plasma could be collected without adverse events. Anti-Ebola virus IgG titres and Ebola-specific neutralizing antibodies in convalescent plasma were only slightly reduced after pathogen reduction treatment with S59 amotosalen/UVA. A patient in Italy with Ebola virus disease was treated with convalescent plasma without apparent adverse effects. A...Continue Reading

References

Aug 6, 1997·JAMA : the Journal of the American Medical Association·D R FranzE M Eitzen
Oct 12, 2000·Clinical Microbiology Reviews·M A Keller, E R Stiehm
Jun 25, 2004·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·Y O Y SooJ J Y Sung
Jan 21, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Ivan Fn HungKwok-Yung Yuen
May 29, 2013·British Journal of Haematology·Axel Seltsam, Thomas H Müller
Apr 18, 2014·The New England Journal of Medicine·Sylvain BaizeStephan Günther
Sep 23, 2014·The New England Journal of Medicine·UNKNOWN WHO Ebola Response TeamZabulon Yoti
Nov 13, 2014·The New England Journal of Medicine·G Marshall LyonUNKNOWN Emory Serious Communicable Diseases Unit
Nov 19, 2014·Proceedings of the National Academy of Sciences of the United States of America·Charles D MurinErica Ollmann Saphire
Nov 20, 2014·The New England Journal of Medicine·J Manuel ParraMaría Velasco
Nov 22, 2014·Science·Jon Cohen, Kai Kupferschmidt
Dec 3, 2014·The Lancet Infectious Diseases·Joseph A LewnardAlison P Galvani
Dec 3, 2014·Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis·Thierry Burnouf, Jerard Seghatchian
Jan 6, 2015·Nature·Declan Butler
Feb 20, 2015·Emerging Infectious Diseases·Thomas R Kreil
Apr 2, 2015·The New England Journal of Medicine·Selidji T AgnandjiClaire-Anne Siegrist
Apr 24, 2015·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Colleen S KraftUNKNOWN Nebraska Biocontainment Unit and the Emory Serious Communicable Diseases Unit
May 21, 2015·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Diana F FlorescuPhilip W Smith
Jun 5, 2015·The Lancet. Respiratory Medicine·Marta Mora-RilloUNKNOWN La Paz-Carlos III University Hospital Isolation Unit
Jun 26, 2015·Journal of Clinical Microbiology·Michael HogardtVolkhard A J Kempf
Aug 2, 2015·The Journal of Infectious Diseases·Olivier Reynard, Viktor E Volchkov
Sep 12, 2015·MMWR. Morbidity and Mortality Weekly Report·Luke BawoUNKNOWN CDC Ebola Response Teams
Oct 17, 2015·BMC Infectious Diseases·Nicola PetrosilloUNKNOWN INMI EBOV Team

❮ Previous
Next ❯

Citations

Aug 27, 2016·Vox Sanguinis·T BurnoufUNKNOWN Global Emerging Pathogens Treatment Consortium (GET)
May 3, 2019·BMC Infectious Diseases·James S LeeRobert A Fowler
Apr 3, 2020·Vox Sanguinis·Pierre TiberghienYazdan Yazdanpanah
Aug 28, 2018·Frontiers in Immunology·Kuldeep DhamaWanpen Chaicumpa
Mar 30, 2017·The New England Journal of Medicine·Johan van GriensvenXavier de Lamballerie
Oct 31, 2020·Transfusion·Freddy T NguyenUNKNOWN Mount Sinai Health System Convalescent Plasma Team
Mar 7, 2021·Transfusion clinique et biologique : journal de la Société française de transfusion sanguine·D Focosi, M Franchini

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Disaster Medicine and Public Health Preparedness
Charles W BeadlingTrueman W Sharp
© 2022 Meta ULC. All rights reserved